Although liquid biopsies encompass a range of possible targets including circulating tumor DNA (ctDNA), circulating tumor cells and exosomes, ctDNA liquid biopsies have been most swiftly adopted in clinical practice. Its utility has been most evident in non-small cell lung cancer (NSCLC).
This white paper will concisely describe Lucence Diagnostics' perspective on ctDNA liquid biopsies in NSCLC in 2020. As a global liquid biopsy service laboratory with operations both in Asia (where 40-50% of NSCLC have EGFR mutation) and the United States (where 10% of NSCLC have EGFR mutation), our shared experience can contribute to wider understanding and advancement of the field.
Please complete this form to download the white paper.